MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, M. B.
Right arrow Articles by Yoburn, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, M. B.
Right arrow Articles by Yoburn, B. C.

Vol. 62, Issue 6, 1464-1470, December 2002

Opioid Agonists Differentially Regulate µ-Opioid Receptors and Trafficking Proteins in Vivo

Minesh B. Patel, Chintan N. Patel, Vikram Rajashekara, and Byron C. Yoburn

Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, New York

Chronic opioid agonist treatment produces tolerance and in some cases opioid receptor internalization and down-regulation. Both morphine and etorphine induce tolerance; however, only etorphine produces µ-opioid receptor (µOR) down-regulation. In vitro studies implicate dynamin-2 (DYN-2) and G-protein receptor kinase-2 (GRK-2) in these processes. Therefore, we examined etorphine and morphine effects on regulation of GRK-2 and DYN-2 in mouse spinal cord. Mice were treated for 7 days with etorphine (200 µg/kg/day infusion) or morphine (40 mg/kg/day infusion + one 25-mg implant pellet). Controls were implanted with a placebo pellet. On the 7th day after implantation mice were tested for i.t. [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) analgesia. In other mice, spinal cord was removed for [3H]DAMGO binding studies or GRK-2 and DYN-2 protein and mRNA abundance were determined. Both etorphine and morphine produced significant tolerance (ED50 shift = 7.6- and 7.3-fold for morphine and etorphine, respectively). Etorphine decreased spinal µOR density by approx 30%, whereas morphine did not change µOR density. Etorphine increased (approx 70%) DYN-2 protein abundance and decreased its mRNA (31%), whereas it had no effect on GRK-2 protein and mRNA abundance. Morphine had no effect on either DYN-2 or GRK-2 protein or mRNA abundance. These data raise the possibility that unequal receptor regulation by etorphine and morphine might be due to differential regulation of trafficking proteins. Overall, receptor down-regulation associated with chronic etorphine treatment may accelerate dynamin-related activity. Finally, the decrease in DYN-2 mRNA may be related to stabilization of DYN-2 protein abundance, which might inhibit transcription.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. S. Virk and J. T. Williams
Agonist-Specific Regulation of {micro}-Opioid Receptor Desensitization and Recovery from Desensitization
Mol. Pharmacol., April 1, 2008; 73(4): 1301 - 1308.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Sirohi, P. Kumar, and B. C. Yoburn
{micro}-Opioid Receptor Up-Regulation and Functional Supersensitivity Are Independent of Antagonist Efficacy
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 701 - 707.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
H. N. Wenk, J.-D. Brederson, and C. N. Honda
Morphine Directly Inhibits Nociceptors in Inflamed Skin
J Neurophysiol, April 1, 2006; 95(4): 2083 - 2097.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Clark and J. R. Traynor
Endogenous Regulator of G Protein Signaling Proteins Reduce {micro}-Opioid Receptor Desensitization and Down-Regulation and Adenylyl Cyclase Tolerance in C6 Cells
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 809 - 815.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
V. C. Dang and J. T. Williams
Chronic Morphine Treatment Reduces Recovery from Opioid Desensitization
J. Neurosci., September 1, 2004; 24(35): 7699 - 7706.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics